RE:As a basis of comparison...To complement this post by Eoganacht...
In "URO TODAY" Dated April 5,2021, by Bishoy M.Faltas, MD, Director of Bladder cancer Research, New York....
Bishoy M.Faltas said " However, pembrolizumab(Keytruda) cost over $100,000 US per year and has a
significant rate of adverse effects. The study revealed that pembrolizumab(Keytruda) was not cost-effective relative to RCx(radical Cystectomy) or SIC(Salvage Intravisical Chemotherapy). Still pembrolizumab was not cost-effective, even with a willingness-to-pay
threshold of $500,000 US". TLT..Safety=Strong safety profile, minimal to no side effects(95% resolved within 180 days).
TLT cost..On TLT website under Market Opportunity.. the cost of each treatments could be
approximately $50,000US( 1 or 2 treatments could to be needed for Complete Response).
The above could give TLT a strong advantage for Bladder Cancer patients choice of treatments.
Eoganacht wrote: In February 2020, the FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. In the keytruda trial that led to this decision 96 patients received 200 mg of pembrolizumab every 3 weeks for up to 2 years or until their disease progressed at which point they were removed from the trial.
At 90 days 41.2% (40 patients) had achieved a CR. At one year 48% of the 40 responding patients (19 patients) were still CR. 19.8% of the original 96 patients had experienced a complete response at one year.
To demonstrate that TLD1433 works as well as Keytruda when they submit their interim data to the FDA, Theralase only needs to report that 5 of the first 25 patients have a CR at 360 days.
A treatment that works as well as Keytruda, has a much better safety profile and only requires one or two treatments, rather than the 17 treatments a year Keytruda requires looks like a very attractive alternative.
Even slightly better efficacy would make TLD1433 a much better choice than Keytruda.